Progress in hematopoietic stem cell transplantation for autoimmune diseases

Area of Science:

• Immunology
• Hematology
• Rheumatology

Background:

• Severe, refractory autoimmune diseases pose significant challenges to existing treatments.
• Hematopoietic stem cell transplantation (HSCT) has emerged as a potential therapeutic option for these debilitating conditions.

Purpose of the Study:

• To evaluate the safety and efficacy of profound immunoablation with HSCT in treating various severe autoimmune diseases.
• To compare outcomes across different autoimmune conditions and explore the impact of varying HSCT protocols.

Main Methods:

• An international Phase I/II program involving nearly 700 patients with autoimmune diseases, including multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and juvenile idiopathic arthritis.
• Treatment-related mortality and clinical outcomes such as remission, relapse, and response rates were assessed.
• Different immunoablative regimens were employed to determine the optimal intensity of treatment.

Main Results:

• An overall treatment-related mortality of 7% was observed, with variations among diseases (e.g., 11% in systemic lupus erythematosus).
• Significant, durable, and clinically useful remissions were achieved across all studied autoimmune diseases.
• More intensive myeloablative regimens did not demonstrate a clear advantage but were associated with increased toxicity.

Conclusions:

• Profound immunoablation with HSCT can induce significant and durable remissions in patients with severe, refractory autoimmune diseases.
• While treatment-related mortality exists, it is manageable and varies by disease.
• The findings support the ongoing development of Phase III randomized trials to further optimize HSCT protocols and confirm efficacy.